Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
UK-396, 082 · 1 trial · 5 indications
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Subjects will be assigned to receive either UK-396,082 or placebo |
| Cohort 2 | EXPERIMENTAL | Subjects will be assigned to receive either UK-396,082 or placebo |
| Cohort 3 | EXPERIMENTAL | Subjects will be assigned to receive either UK-396,082 or placebo |
| Cohort 4 | EXPERIMENTAL | Subjects will be assigned to receive either UK-396,082 or placebo |
| Name | Type | Description |
|---|---|---|
| UK-396,082 | DRUG | 100mg given orally twice daily for 14 days The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose. |
| placebo | DRUG | given orally twice daily for 14 days |
Inclusion Criteria: * Healthy subjects. (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests). Exclusion Criteria: * Evidence ...
UK-396,082 is an investigational small molecule being developed by Pfizer, Inc. (PFE). It is currently in Phase 1 clinical development. The drug has been studied in healthy volunteers to assess its safety, toleration, and pharmacokinetics.
UK-396,082 is being investigated for use in a Phase 1 setting. The completed clinical trial focused on evaluating the safety, toleration, and time course of blood concentration of the drug after multiple oral doses in healthy people. Its specific therapeutic indication has not been established.
UK-396,082 is being developed by Pfizer, Inc., which is publicly traded under the ticker symbol PFE. The company conducted a Phase 1 clinical trial of the drug in healthy volunteers.
UK-396,082 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and no active trials are currently listed.
UK-396,082 has one completed clinical trial registered as NCT01091532. This Phase 1 study enrolled 48 healthy participants in Belgium and evaluated the safety, toleration, and pharmacokinetics of multiple oral doses of the drug. The trial was randomized, double-blind, and controlled.
No alternative names for UK-396,082 have been reported. The drug is identified by its code name UK-396,082 in clinical trial registrations and is developed by Pfizer, Inc.